Drug
Enasidenib clinical trials
Also written AG-221, Idhifa and CC-90007.
- studies test it
- 37
- open now
- 11
- in phase 3
- 3
- first study started
- 2013
Keep track of what changes. Save the enasidenib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
37 studies that test it; most in 2019 (6)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 20
- Phase 2
- 22
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 27
Celgene (9) · National Cancer Institute (NCI) (4) · Memorial Sloan Kettering Cancer Center (3) · M.D. Anderson Cancer Center (3) · City of Hope Medical Center (2) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · Groupe Francophone des Myelodysplasies (1) · Institut de Recherches Internationales Servier (1)
Often tested with
Tested in the same studies.
Ivosidenib (8) · Venetoclax (7) · Azacitidine (4) · Daunorubicin (3) · Cobimetinib (3) · Cytarabine (3) · Gilteritinib (3) · CPX-351 (2)
Studies
Open first, then newest update. How each study uses enasidenib is read from its arms, and is right about nine times in ten.
Testing it · 37
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Enasidenib
- Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06577441Written as Enasidenib
- Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT06176989Written as Enasidenib
- Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06672146Written as Enasidenib
- Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in RemissionRecruitingPhase 1M.D. Anderson Cancer CenterNCT05010772Written as Enasidenib
- Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationRecruitingPhase 2M.D. Anderson Cancer CenterNCT03683433Written as Enasidenib Mesylate
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as AG-221 (BAML-16-001-S3)
- Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized TrialRecruitingPhase 2Washington University School of MedicineNCT06240754Written as Enasidenib
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Enasidenib
- IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)RecruitingPhase 2Alice MimsNCT05401097Written as Enasidenib
- Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT04774393Written as Enasidenib
- A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)Active, not recruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT05756777Written as Enasidenib
- A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive ChemotherapyActive, not recruitingPhase 3Stichting Hemato-Oncologie voor Volwassenen NederlandNCT03839771Written as AG-221
- Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 MutationSuspendedPhase 2City of Hope Medical CenterNCT03728335Written as Enasidenib Mesylate
- A Study of Enasidenib in People With T-Cell LymphomaActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06756308Written as Enasidenib
- IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic SyndromeActive, not recruitingPhase 2Groupe Francophone des MyelodysplasiesNCT03744390Written as AG-221
- Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 MutationActive, not recruitingPhase 1Institut de Recherches Internationales ServierNCT02632708Written as AG-221
- Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 1City of Hope Medical CenterNCT05441514Written as Enasidenib Mesylate
- A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction ChemotherapyActive, not recruitingPhase 1/2CelgeneNCT02677922Written as AG-221
- A Study of Enasidenib in People With Clonal Cytopenia of Undetermined SignificanceCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT05102370Written as Enasidenib
See all 37 studies that test enasidenib →
Given in every arm · 6 — enasidenib is usual care beside what is tested
- Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromeRecruitingPhase 2M.D. Anderson Cancer CenterNCT03383575Written as Enasidenib
- A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative NeoplasmsWithdrawnPhase 1University of ChicagoNCT04955938Written as Enasidenib
- A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid LeukemiaCompletedPhase 1Jazz PharmaceuticalsNCT04075747Written as Enasidenib
- Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationWithdrawnPhase 1City of Hope Medical CenterNCT04655391Written as Enasidenib Mesylate
- Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene MutationWithdrawnPhase 2Roswell Park Cancer InstituteNCT03881735Written as Enasidenib
- Radiolabeled Study of AG-221 in Healthy Male Subjects.CompletedPhase 1CelgeneNCT02443168Written as AG-221
Codes
What other systems call enasidenib · ClinicalTrials.gg INT000407
- MeSH (NLM) C000605269enasidenibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3T1SS4E7AGENASIDENIBConfirmed FDA, NLM, Wikidata
- RxNorm 1940332Confirmed FDA, Wikidata
- Wikidata Q27077182enasidenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C111573EnasidenibConfirmed FDA, Wikidata
- DrugBank DB13874One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000605269 | enasidenib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3T1SS4E7AG | ENASIDENIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1940332 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27077182 | enasidenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C111573 | Enasidenib | Confirmed FDA, Wikidata |
| DrugBank | DB13874 | — | One source Wikidata |
Also registered as enasidenib mesylate (UNII UF6PC17XAV · RxNorm 1940331).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.